癌症谵妄终末期激越的抗精神病药策略随机试验
这项单中心、双盲、平行组随机试验在MD Anderson癌症中心姑息治疗病房纳入45例低剂量氟哌啶醇无效的终末期谵妄激越患者,比较氟哌啶醇剂量递增、氯丙嗪转换及两药联合三种策略。
要点
- 三种抗精神病药策略均显著降低终末期谵妄激越的RASS评分,组间无差异。
- 最常见严重毒性为低血压,递增组40%、转换组31%、联合组21%,无治疗相关死亡。
核心结论
- 三种抗精神病药策略(氟哌啶醇剂量递增、氯丙嗪转换、两药联合)均可能减轻终末期激越,组间无显著差异。
研究设计与样本
- 单中心、双盲、平行组随机试验,纳入MD Anderson癌症中心姑息与支持治疗病房45例接受盲法干预的晚期癌症患者。
- 主要终点为0至24小时RASS评分变化,采用改良意向性分析比较组间差异。
主要发现
- RASS评分在30分钟内显著下降并在24小时维持低水平。
- 最常见严重毒性为低血压:递增组6例(40%)、转换组5例(31%)、联合组3例(21%),无治疗相关死亡。
临床怎么用
- 对低剂量氟哌啶醇无效的终末期谵妄激越患者,可考虑氟哌啶醇剂量递增、氯丙嗪转换或两药联合策略。
- 使用上述策略时需监测低血压等严重毒性。
局限性
- 单中心设计。
- 样本量小。
- 缺乏仅安慰剂对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of neuroleptics for terminal agitated delirium is controversial. We assessed the effect of three neuroleptic strategies on refractory agitation in patients with cancer with terminal delirium. METHODS: In this single-centre, double-blind, parallel-group, randomised trial, patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation, despite low-dose haloperidol, were randomly assigned to receive intravenous haloperidol dose escalation at 2 mg every 4 h, neuroleptic rotation with chlorpromazine at 25 mg every 4 h, or combined haloperidol at 1 mg and chlorpromazine at 12·5 mg every 4 h, until death or discharge. Rescue doses identical to the scheduled doses were administered at inception, and then hourly as needed. Permuted block randomisation (block size six; 1:1:1) was done, stratified by baseline Richmond Agitation Sedation Scale (RASS) scores. Research staff, clinicians, patients, and caregivers were masked to group assignment. The primary outcome was change in RASS score from time 0 to 24 h. Comparisons among group were done by modified intention-to-treat analysis. This completed study is registered with ClinicalTrials.gov, NCT03021486. FINDINGS: Between July 5, 2017, and July 1, 2019, 998 patients were screened for eligibility, with 68 being enrolled and randomly assigned to treatment; 45 received the masked study interventions (escalation n=15, rotation n=16, combination n=14). RASS score decreased significantly within 30 min and remained low at 24 h in the escalation group (n=10, mean RASS score change between 0 h and 24 h -3·6 [95% CI -5·0 to -2·2]), rotation group (n=11, -3·3 [-4·4 to -2·2]), and combination group (n=10, -3·0 [-4·6 to -1·4]), with no difference among groups (p=0·71). The most common serious toxicity was hypotension (escalation n=6 [40%], rotation n=5 [31%], combination n=3 [21%]); there were no treatment-related deaths. INTERPRETATION: Our data provide preliminary evidence that the three strategies of neuroleptics might reduce agitation in patients with terminal agitation. These findings are in the context of the single-centre design, small sample size, and lack of a placebo-only group. FUNDING: National Institute of Nursing Research.
引用
- Hui D, De La Rosa A, Wilson A, et al. Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial. Lancet Oncol. 2020. PMID: 32479786. doi:10.1016/S1470-2045(20)30307-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。